JPRN-UMIN000021157
Completed
未知
Clinical trial for efficacy and safety related to weekly dosage regimens of methotrexate - Clinical trial for Adverse event related to Weekly dosage regimens of Methotrexate (ADDMe trial)
Yokohama Minami Kyousai Hospital0 sites120 target enrollmentFebruary 29, 2016
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Yokohama Minami Kyousai Hospital
- Enrollment
- 120
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •(Complication) Patients who had any of the following diagnoses or medical history 1\)Autoimmune disease, except for RA and Sjogren's syndrome, and malignancy. 2\)Drug allergy 3\)Severe heart, lung, liver, kidney and heamatological disorders (Treatment) 4\)Patient who recived intramuscular, intoravenous or epidural injection of corticosteroids within 4 weeks prior to the entry or during study 5\)Patient who recived intraarticular corticosteroid at dose of over 20mg/month of prednisolone, and at any dose within 4weeks prior to study entry or first end point 6\)Pateint whose body weight is less than or equal to 40kg 7\)Patient who recived systemic corticosteroid with a dose of\>10mg of predonisolone within 4 weeks prior to the study or during the study and patients whose corticosteroid dose were changed within 4 weeks prior to first end point 8\)Patient who received NSAIDs with an overdosage within 4 weeks prior to the study entry or during the study. 9\) Patient who is currently under treatment or treatmented with biologics, JAK inhibitor or immunosappressants within 8 weeks prior to the study entry. (Surgery) 10\)Patient who had surgery judged to have an influence on this study by doctor 11\)Patient who had the following treatment or procedure:plasma exchange, leukocyte depleted therapy or arthrocentesis against affected joint. except for the arthrocenesis following intraarticular injection of corticosteroid, within 4 weeks prior to the study entry or during the study (Others) 12\)Patient who is in pregnancy, lactating, or with a possibility of the pregnancy and woman who hopes for pregnancy during study or within 1 month after the end of this study, and man who wishes his partner be pregnant during the study or within 3 months after the end of this study 13\)Patient who can not go to a hospital for check\-up on an appointed day 14\)When principal investigator or sub investigators of this study judge the patients disqualified as a subject of this study
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Clinical trial on the safety and effectiveness of Tissue Therapies extracellular matrix on healing of venous leg ulcersVenous Leg UlcersSkin - Other skin conditionsCardiovascular - Diseases of the vasculature and circulation including the lymphatic systemACTRN12611000132943Tissue Therapies Ltd58
Completed
Not Applicable
Clinical trial on the usefulness and the safety of imidazole antifungal topical agent; ketoconazole cream for acne vulgarisacne vulgarisJPRN-UMIN000020494Fujita Health University30
Completed
Phase 3
Clinical trial of S-Metoprolol and Telmisartan combination tablet in the treatment of hypertensioCTRI/2011/06/001819Emcure Pharmaceuticals Ltd Pune200
Completed
Phase 2
Clinical trial to assess the efficacy and safety of TNK-TPA in Acute Ischemic StrokeCTRI/2009/091/000251Gennova Biopharmaceuticals Limited Pune50
Completed
Phase 3
A phase III clinical trial study to evaluate the efficacy and safety of Tenecteplase (TNK-TPA) in Acute Ischemic Stroke patientsCTRI/2015/02/005556Gennova Biopharmaceuticals Ltd62